XHANCE (fluticasone propionate)
Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
Key Facts
About Paratek Pharmaceuticals
Paratek Pharmaceuticals is a mission-driven, commercial-stage biopharma focused on creating 'Positive Patient Stories®' by tackling serious infectious diseases and chronic inflammatory conditions. The company has successfully transitioned from R&D to a fully integrated commercial entity with two marketed products: NUZYRA® (omadacycline), a modern tetracycline antibiotic, and XHANCE® (fluticasone propionate), a novel-delivery nasal spray. Its strategy leverages deep expertise in tetracycline chemistry and targeted drug delivery to serve substantial specialty markets while addressing critical public health threats like antimicrobial resistance.
View full company profileAbout Paratek Pharmaceuticals
Paratek Pharmaceuticals is a mission-driven, commercial-stage biopharma focused on creating 'Positive Patient Stories®' by tackling serious infectious diseases and chronic inflammatory conditions. The company has successfully transitioned from R&D to a fully integrated commercial entity with two marketed products: NUZYRA® (omadacycline), a modern tetracycline antibiotic, and XHANCE® (fluticasone propionate), a novel-delivery nasal spray. Its strategy leverages deep expertise in tetracycline chemistry and targeted drug delivery to serve substantial specialty markets while addressing critical public health threats like antimicrobial resistance.
View full company profileAbout Paratek Pharmaceuticals
Paratek Pharmaceuticals is a mission-driven, commercial-stage biopharma focused on creating 'Positive Patient Stories®' by tackling serious infectious diseases and chronic inflammatory conditions. The company has successfully transitioned from R&D to a fully integrated commercial entity with two marketed products: NUZYRA® (omadacycline), a modern tetracycline antibiotic, and XHANCE® (fluticasone propionate), a novel-delivery nasal spray. Its strategy leverages deep expertise in tetracycline chemistry and targeted drug delivery to serve substantial specialty markets while addressing critical public health threats like antimicrobial resistance.
View full company profileAbout Paratek Pharmaceuticals
Paratek Pharmaceuticals is a mission-driven, commercial-stage biopharma focused on creating 'Positive Patient Stories®' by tackling serious infectious diseases and chronic inflammatory conditions. The company has successfully transitioned from R&D to a fully integrated commercial entity with two marketed products: NUZYRA® (omadacycline), a modern tetracycline antibiotic, and XHANCE® (fluticasone propionate), a novel-delivery nasal spray. Its strategy leverages deep expertise in tetracycline chemistry and targeted drug delivery to serve substantial specialty markets while addressing critical public health threats like antimicrobial resistance.
View full company profileTherapeutic Areas
Other Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Drugs
| Drug | Company | Phase |
|---|---|---|
| Verekitug (UPB-101) | Upstream Bio | Phase 2 |